We then established ARF1-deficient HT29 and DLD1 cell lines for validation and found that ARF1 knockout significantly attenuated the inhibitory effect of azelastine on CRC cell proliferation (Figure S5D-E), illustrating that azelastine directly targeted ARF1 to suppress CRC growth. This evidence concerns the gene ARF1 and colorectal carcinoma.